Jefferson University Hospitals

Jefferson Participates in National Study to Test HeartMate III™ for Advanced Heart Failure



This week, Thomas Jefferson University Hospital announced its participation in a national, multi-center trial to test the HeartMate 3™ Left Ventricular Assist Device (LVAD). The trial will evaluate the performance and safety of a new, investigational LVAD – which is an implantable device that circulates blood throughout the body when the heart is too weak to pump blood adequately on its own, a diagnosis known as advanced heart failure.

“Jefferson is excited to be the first hospital in the Philadelphia region to enroll a patient in this national trial, which will evaluate the HeartMate 3 LVAD,” said John Entwistle III, MD, PhD, Associate Professor of Cardiothoracic Surgery in the Sidney Kimmel Medical College at Thomas Jefferson University and Surgical Director of Cardiac Transplantation and Mechanical Circulatory Support. “LVAD technologies can help some patients with advanced heart failure resume their usual daily activities without shortness of breath. The heart failure team at Jefferson is dedicated to state-of-the-art research that tests treatments for this devastating disease.”

“Heart failure affects more than 5 million Americans and is diagnosed in 800,000 new patients per year,” said Paul Mather, MD, FACC., FACP, the Lubert Family Professor of Cardiology and Director of the Advanced Heart Failure and Transplant Center at the Jefferson Heart Institute. “The symptoms have a huge impact on our patients’ overall wellbeing and quality and length of life. Jefferson is committed to testing advances that could help patients with this diagnosis.”

The trial is expected to enroll more than 1,000 patients nationwide and compares the HeartMate 3 to the HeartMate II. To be considered for the trial, patients:

• will have heart failure symptoms that are difficult to manage, even with medical treatment,

• are unable to perform physical activity without discomfort,

• have noticed a decline in quality of life due to the disease,

• have been hospitalized one or more times for heart failure in the past six months 

For more information about this trial, patients and physicians can contact Jefferson’s Advanced Heart Failure and Cardiac Transplant Center at 215-955-2050.

Media Only Contact:
Gail Benner
Jefferson University Hospitals
Phone: 215-955-2240